Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes

By  

Current Drug Safety, Vol. 6, Iss. 5, 2011-11 ,pp. : 304-309

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on β‐cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对β细胞功能的影响：一项meta分析

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 3, 2015-05 ,pp. : 347-359

John Wiley & Sons Inc

Access to resources Recommend Favorite

Circulating dipeptidyl peptidase‐4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non‐alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross‐sectional study

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 6, 2015-11 ,pp. : 809-819

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

By Herman Gary A.   Bergman Arthur   Yi Bingming   Kipnes Mark    

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 1939-1947

Informa Healthcare

Access to resources Recommend Favorite

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf   Herman Gary A.   Wu Mei   Mickel Carolyn   Sanchez Matilde   Stein Peter P.    

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite